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Background: The pancreas is one of the primary organs affected by dysfunction of the cystic ﬁbrosis transmembrane conductance regulator
(CFTR) protein. While exocrine pancreatic insufﬁciency is a well-recognized complication of cystic ﬁbrosis (CF), symptomatic pancreatitis is
often under-recognized.
Results: The aim of this review is to provide a general overview of CFTR mutation-associated pancreatitis, which affects patients with pancreatic
sufﬁcient CF, CFTR-related pancreatitis, and idiopathic pancreatitis. The current hypothesis regarding the role of CFTR dysfunction in the
pathogenesis of pancreatitis, and concepts on genotype–phenotype correlations between CFTR and symptomatic pancreatitis will be reviewed.
Symptomatic pancreatitis occurs in 20% of pancreatic sufﬁcient CF patients. In order to evaluate genotype–phenotype correlations, the
Pancreatic Insufﬁciency Prevalence (PIP) score was developed and validated to determine severity in a large number of CFTR mutations. Speciﬁc
CFTR genotypes are signiﬁcantly associated with pancreatitis. Patients who carry genotypes with mild phenotypic effects have a greater risk of
developing pancreatitis than patients carrying genotypes with moderate–severe phenotypic consequences at any given time.
Conclusions: The genotype–phenotype correlation in pancreatitis is unique compared to other organ manifestations but still consistent with the
complex monogenic nature of CF. Paradoxically, genotypes associated with otherwise mild phenotypic effects have a greater risk for causing
pancreatitis; compared with genotypes associated with moderate to severe disease phenotypes. Greater understanding into the underlying
mechanisms of disease is much needed. The emergence of CFTR-assist therapies may potentially play a future role in the treatment of CFTR-
mutation associated pancreatitis.
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Fig. 1. Histopathological features of chronic pancreatitis in CF.1. Introduction
Cystic fibrosis (CF), termed after the autopsy findings of
“cystic fibrosis of the pancreas” in malnourished infants [1], is
caused by mutations in the gene that encodes for the cystic fibrosis
transmembrane conductance regulator (CFTR) protein [2]. The
CFTR protein functions on the apical surface of epithelial cells as
a cyclic AMP-dependent chloride channel, a bicarbonate channel
and as amodulator of other ion channels [3–8]. CFTR is located in
the apical membrane of secretory and absorptive epithelial cells of
the pancreas, intestine, liver, airway, vas deferens and sweat
glands. Absence or defective function of the protein product is
directly or indirectly responsible for disease pathogenesis in CF-
affected organs. The manifestations of CF generally arise when
ductal or glandular obstruction occurs due to an inability to
hydrate macromolecules within affected ductal lumens.
Functionally, the pancreas can be divided into its exocrine and
endocrine components. The former is comprised of pancreatic
acinar and ductular cells, while the latter is primarily composed of
pancreatic islet cells. Although CFTR is predominantly expressed
in the pancreatic ductal epithelium, both exocrine and endocrine
components of the pancreas are affected, to varying degrees, in
CF. In health, the human pancreatic ductal epithelium secretes
large volumes (1–2 L/day) of alkaline fluid made of sodium
chloride and bicarbonate, as well as other cations (e.g. potassium)
[9,10]. The pancreatic secretion is physiologically intended to
flush digestive enzymes secreted by pancreatic acinar cells down
the pancreatic–biliary tree and into the duodenum. The alkaline
solution also functions to alkalinize acidic chyme emptied from
the stomach into the duodenum, and to provide the optimal pH
milieu for pancreatic digestive enzyme activity. In CF disease,
exocrine pancreatic damage in its severe form is known as
pancreatic insufficiency (PI). Pancreatic damage begins in utero
and continues into infancy or early childhood when complete loss
of pancreatic acinar tissue occurs [11,12]. Only 1–2% of residual
pancreatic reserve is required to maintain pancreatic sufficiency
(PS). In contrast to PI CF, patients with PS CF have sufficient
exocrine pancreatic function to maintain normal nutrient digestion
without the use of pancreatic enzyme supplements. In CF,
pancreatic secretions have lower fluid volumes and increased
acidity within the pancreatic lumen which leads to precipitation of
the protein rich secretions, causing plugging of small ducts,
obstruction, and progressive damage to the pancreas (Fig. 1).
Despite the progressive destruction of the acinar pancreas by
inflammation and fibrosis the vast majority of PI individuals have
no clinical manifestations of pancreatitis in early life.Among all the different organ systems affected, the exocrine
pancreas is the most reliable phenotypic barometer of CFTR
function [13,14]. Most CF patients carrying functionally severe
mutations on both alleles have a PI phenotype [13–16]. A small
proportion of patients carrying severe mutations on both alleles
are PS at diagnosis, but most progressively transition from PS to
PI state. Patients who carry a mild mutation on at least one allele,
which confers some residual ion channel function, usually have
sufficient exocrine pancreatic function to allow normal digestion
of nutrients. Thus, mutations that confer the pancreatic sufficient
phenotype do so in a dominant fashion. PS CF patients are often
diagnosed at an older age, notably in adolescence and adulthood
and present with more subtle disease manifestations and lower
sweat chloride concentrations than PI CF patients [14,17].
2. Pancreatitis in CF and CFTR-related disorder
Symptomatic pancreatitis is a well known but uncommon
manifestation in CF disease because it occurs exclusively in PS
CF patients and not in patients with PI CF [15,16,18,19]. This is
not surprising since the presence of a “critical mass” of pancreatic
acinar tissue is necessary for symptomatic pancreatitis to occur
and considering that the majority of CF patients (85–90%) who
carry functionally severeCFTRmutations on both alleles have PI.
Therefore, the vast majority of individuals with severe mutations
on both alleles do not develop symptomatic pancreatitis.
Approximately, 20% of PS CF patients develop pancreatitis,
while the rest do not [15,16,19].
In addition, to PS CF patients, individuals with so-called
“idiopathic” recurrent-acute or chronic pancreatitis have an
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Bishop et al. reported that 43% and 11% of patients with
idiopathic recurrent-acute or chronic pancreatitis carried at least
one, and two CFTRmutations (and/or variants), respectively [22].
On thorough evaluation with sweat test, genotyping and nasal
potential difference testing, the diagnostic criteria of CF could be
fulfilled in 21% of these patients. The remaining individuals who
did not fulfill the diagnostic criteria for CF but have evidence of
CFTR dysfunction on sweat chloride and/or NPD testing but
insufficient dysfunction to diagnose CF (e.g. sweat chloride values
in the intermediate range) may be diagnosed as having a CFTR-
related disorder.able 1
erivation of the Pancreatic Insufficiency Prevalence (PIP) score, and comparison
etween PIP and the traditional 5-class system.
dapted from Ooi et al. [19].
Total PI Total PI+PS PIP score
621+1G>T 96 96 1.00 Classes I - III
711+1G>T 36 36 1.00 Classes I - III
R553X 24 24 1.00 Classes I - III
I507del 34 34 1.00 Classes I - III
G542X 74 75 0.99 Classes I - III
F508del 1276 1324 0.96 Classes I - III
1717-1G>A 20 21 0.95 Classes I - III
W1282X 19 20 0.95 Classes I - III
N1303K 45 48 0.94 Classes I - III
R1162X 12 13 0.92 Classes I - III
G551D 59 67 0.88 Classes I - III
G85E 16 22 0.73 Classes I - III
A455E 18 37 0.49 Classes IV - V
Mutation
Canadian Consortium for CF Genetic Studies
Mutation class3. Pathogenesis
There are complex interactions between the ductular and acinar
components of the pancreas in the development of pancreatitis.
Each component is further influenced by various genetic and
environmental factors. While an obstructive tubulopathy of the
pancreas due to the CFTR dysfunction is thought to be the primary
initiating factor, the exact pathogenic process of pancreatitis
associated with CFTR mutations is still under investigation.
Recent studies suggest an important role of CFTR in the
development of pancreatitis, particularly through its role in
intraluminal pH regulation from bicarbonate (alkaline) secretion
and the flushing of ductal proteins. Secretory granules of
pancreatic acinar cells co-release protons (H+) with digestive
enzymes during normal pancreatic secretion [23]. Diminished
ductal bicarbonate secretion and consequent reduced alkaliniza-
tion of the acinar lumen may promote the development of
pancreatitis since acidification of the pancreatic lumen can lead to
a loss of tight junction integrity, allowing the leakage of digestive
enzymes into the pancreatic duct lumen and interstitial space.
Decrease in pH within the ductal lumen is also associated with
acceleration of trypsinogen autoactivation into trypsin, initiating
the early stages of autodigestion of the pancreas by pancreatic
enzymes. The presence of active trypsin in the pancreatic duct
lumen may lead to additional reduction in bicarbonate secretion
due to inhibition of CFTR and other luminal anion exchangers
(e.g. SLC26) via proteinase-activated receptor 2 [24]. Further
reduction in bicarbonate secretion by the ductal epithelium
generates a vicious cycle and environment of falling pH,
enhanced trypsinogen activation and decreased intraluminal
fluid volume, which promotes the development of pancreatitis.2789+5G>A 6 16 0.38 Classes IV - V
R334W 1 10 0.10 Classes IV - V
3849+10kbC>T 2 22 0.09 Classes IV - V
R117H 1 25 0.04 Classes IV - V
he PIP score for a specific mutation is the ratio between the pancreatic insufficient
atients carrying the mutation (Total PI) and all pancreatic insufficient and
ufficient patients (Total PI+PS) carrying the same mutation in a homozygous
tate or heterozygous in a combination with a severe mutation such as F508del,
551D or a Class I mutation. For example, a ratio of 1.00 indicates that all patients
ith 621+1 GNT are PI when associated with a severe mutation on the other allele.
imilarly, a ratio of 0.1 demonstrates that 10% of subjects with R334W are PI.
utations were classified as either “mild” (≤0.25; shaded gray) or “severe”
N0.25) on the basis on the PIP score. The PIP scores derived from the Canadian
ohort were validated against subjects from the Verona CF Centre.4. CFTR mutations
Since the discovery of the CFTR gene in 1989, advances in
molecular analysis techniques have identified N1800 CFTR
mutations. In this context, the term mutation, simply refers to a
molecular alteration in the DNA sequence of a gene, with no
inference made regarding the effect of this alteration on gene
expression, protein function and, therefore, clinical phenotype.
The effect of the mutation on gene expression or function of the
protein product is still unknown for many of the CFTRmutations
which have been identified. This is especially true for missensemutations which represent approximately 40% of the identified
mutations.
A 5-class classification system for CFTR mutations was
originally developed to categorize the molecular characteristics of
different mutations [25]. On the basis of its molecular defect,
mutations in Classes I–III were predicted to have severe functional
and phenotypic consequences. Conversely, mutations belonging to
Classes IV and V may confer residual CFTR function and thus, be
predicted to be associated with milder phenotypic consequences.
Remarkably, genotype–phenotype studies of the exocrine pancre-
atic function status demonstrated an excellent correlation between
Classes I–III with a PI phenotype, and Classes IV–V with a PS
phenotype [13,14]. A 6th mutation class has subsequently been
proposed which is also associated with severe functional and
phenotypic consequences.
Although this 5-class system is useful as a conceptual
framework, it has several limitations [19,26] which include:
(i) molecular changes of different mutations within the same class
(especially Classes IV and V), may have varying functional
consequences, (ii) mutations may have overlapping molecular
defects which may be assigned to more than one class, (iii) the
molecular consequences of the majority of rare CFTR mutations,
particularly missense alterations are unknown or cannot beT
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Table 2
The Pancreatic Insufficiency Prevalence (PIP) score for various CFTR mutations. Only mutations identified in ≥2 subjects are listed. The PIP score of rare mutations
(e.g. identified in b4 subjects) should be interpreted with care.
CFTR mutation Total PI Total PI + PS PIP score CFTR mutation Total PI Total PI + PS PIP score
621+1G>T 96 96 1.00 G542X 74 75 0.99
711+1G>T 36 36 1.00 F508del 1276 1324 0.96
I507del 34 34 1.00 1717-1G>A 20 21 0.95
R553X 24 24 1.00 W1282X 19 20 0.95
Q493X 11 11 1.00 N1303K 45 48 0.94
S489X 11 11 1.00 R1162X 12 13 0.92
1154insTC 10 10 1.00 Y1092X 12 13 0.92
3659delC 9 9 1.00 I148T 10 11 0.91
CFTRdele2 7 7 1.00 V520F 9 10 0.90
4016insT 7 7 1.00 G551D 59 67 0.88
E60X 7 7 1.00 L1077P 5 6 0.83
R560T 7 7 1.00 R1066C 5 6 0.83
R1158X 7 7 1.00 2184insA 9 12 0.75
3905insT 6 6 1.00 2143delT 3 4 0.75
I148T;3199del6 5 5 1.00 1161delC 3 4 0.75
2183AA>G 5 5 1.00 3120+1G>A 3 4 0.75
1898+1G>A 5 5 1.00 S549N 3 4 0.75
2347delG 4 4 1.00 G85E 16 22 0.73
Q1313X 3 3 1.00 R117C 2 3 0.67
Q220X 3 3 1.00 M1101K 19 30 0.63
2184delA 3 3 1.00 P574H 3 5 0.60
1078delT 3 3 1.00 474del13BP 1 2 0.50
L1254X 3 3 1.00 R352Q 1 2 0.50
E585X 3 3 1.00 Q1291H 1 2 0.50
3876delA 2 2 1.00 A455E 18 37 0.49
S4X 2 2 1.00 R347P 6 15 0.40
R1070Q 2 2 1.00 2789+5G>A 6 16 0.38
F508C 2 2 1.00 L206W 6 18 0.33
DELI507 2 2 1.00 IVS8-5T 4 16 0.25
Q1411X 2 2 1.00 3272-26A>G 1 4 0.25
365-366insT 2 2 1.00 R334W 1 10 0.10
R709X 2 2 1.00 3849+10kbC>T 2 22 0.09
1138insG 2 2 1.00 P67L 1 14 0.07
CFTRdele2-4 2 2 1.00 R117H 1 25 0.04
3007delG 2 2 1.00 R347H 0 5 0.00
Q814X 2 2 1.00 G178R 0 3 0.00
394delTT 2 2 1.00 E116K 0 2 0.00
406-1G>A 2 2 1.00 875+1G>C 0 2 0.00
R75X 2 2 1.00 V232D 0 2 0.00
CFTRdel2-3 2 2 1.00 D579G 0 2 0.00
E193X 2 2 1.00 L1335P 0 2 0.00
185+1G>T 2 2 1.00
Mild mutations (based on PIP scores) are shaded in gray.
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Fig. 2. Survival curves comparing time to pancreatitis in patients grouped
according to severity of CFTR genotype. (A) Kaplan-Meier estimate of the
proportion of pancreatic sufficient CF patients who have not developed
pancreatitis through to the age of 50 years for mild and severe CFTR genotype
groups. (B) Kaplan-Meier estimate of the proportion of pancreatic sufficient CF
patients who have not developed pancreatitis through to the age of 50 years
stratified according to the severity of both CFTR alleles.
Adapted from Ooi et al. [19].
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Fig. 3. A conceptual model demonstrating CFTR-related factors that contribute
to pancreatitis. Development of pancreatitis is associated with the opposing
factors of severity of ductal obstruction and degree of pancreatic acinar reserve
(refer text for details).
Adapted from Ooi et al. [19].
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be confirmed by functional studies. Indeed, the inability to predict
functional severity and clinical consequence in the majority of
CFTR mutations beyond the traditional 5 class system has limited
previous studies in genotype–phenotype correlations in pancrea-
titis. Since pancreatitis in CF is limited to PS CF patients with
residual CFTR function, most pancreatitis affected individuals
carry uncommon to rare missense CFTR mutations, which are
usually those of uncertain functional consequences (or mutation
class).To address these limitations, we recently developed and
validated a novel classification system for mutation severity,
known as the Pancreatic Insufficiency Prevalence (PIP) score
[19]. Classification by the PIP score is based on several premises:
(1) the well-established correlation between severity of CFTR
mutations and exocrine pancreatic function, (2) the dominant
phenotypic effect conferred by the milder of the two CFTR
mutations, and (3) the availability of a comprehensive database
containing large numbers of CF patients with stringent clinical
diagnosis and exocrine pancreatic status determination. Since the
Canadian Consortium for CF Genetic Studies and Verona CF
Centre databases fulfilled the latter criterion, we developed
derivation and validation cohorts respectively, for the PIP score
(Table 1). Exocrine pancreatic status was determined objectively
in all patients and not purely based on unreliable methods such as
clinical symptoms suggesting steatorrhoea or the use of
pancreatic enzyme replacement therapy. The PIP score for a
specific mutation is calculated based on the ratio between PI
patients carrying the mutation and all PI and PS patients carrying
the same mutation in a homozygous state or heterozygous in a
combination with mutations known to have severe consequences,
such as F508del or most Class I mutations (Table 1 legend). A
PIP score could only be assigned to patients with identified
mutations on both alleles based on the lowest PIP score of the two
identified mutations. A PIP score for very rare mutations should
be interpreted with caution due to derivation from very small
number of subjects. The PIP scores of CFTRmutations identified
from subjects in the Canadian Consortium for CFGenetic Studies
database are shown in Table 2.
The PIP scoring system permitted a more refined classification
of the functional severity of CFTR mutations (than can be
provided by the conventional 5 class system) and in a far greater
number of patients than previous method(s) of classification.
Thus the scoring system can be applied to other studies and
360 C.Y. Ooi, P.R. Durie / Journal of Cystic Fibrosis 11 (2012) 355–362settings. Categorically, mutations can be classified as either mild
(≤0.25) or severe (N0.25) on the basis of the PIP score.
5. Genotype and phenotype correlations
Several key factors have previously impeded in-depth
evaluation of the relationship between CFTR mutations and
pancreatitis. Earlier studies which defined the association ofCFTR
mutations with idiopathic recurrent-acute or chronic pancreatitis
used commercially available screening panels of the most
common CF-causing mutations, most of which resulted in PI
exocrine status rather than mutations commonly found in subjects
with PS. Even with the availability of gene sequencing, the
inability to predict/classify the functional severity of a large
majority of CFTR mutations remains. Furthermore, symptomatic
pancreatitis is an uncommon manifestation in CF which occurs
almost exclusively in PS CF patients; this makes genotype–
phenotype correlation studies difficult due to sample size
limitations.
These limitations are noteworthy since findings based on
previous studies which did not control for the above-mentioned
issues have become contentious. For example, an earlier report,
suggested that the risk of developing CFTR mutation-associated
pancreatitis was greatest in individuals who carried compound
heterozygote genotypes containing 1 severe plus 1 mild-variable
mutation [27]. Thereafter, it was suggested that CFTR mutation-
associated pancreatitis can be divided into 4 subtypes [28]: (1)
Type 1 is “classic” CF with two severe alleles; (2) Type 2 is
“atypical” CF with compound heterozygosity with a severe and
mild-variable mutation; (3) Type 3 is CFTR mutation(s) plus a
second susceptibility gene (e.g. SPINK1 as gene modifier); and
(4) Type 4 is a compound heterozygote with a severe or mild-
variable allele plus a strong environmental modifier factor
(e.g. heavy alcohol consumption). In contrast, our own findings
suggest that subjects who carry two mild mutations [19] have the
highest risk of CF-associated pancreatitis and terminologies of
“classic” and “atypical” CF are no longer recommended [29].
In the largest systematic study to date, involving 277 PS CF
subjects with and without pancreatitis, we demonstrated that the
risk of pancreatitis was associated with severity ofCFTR genotype
[19]. This study was designed to address the aforementioned
limitations and utilized a study cohort composed only of
objectively confirmed PS CF patients with 2 identified CFTR
mutations, thereby allowing a more refined focus on CFTR as the
primary pathogenic factor and unlike other studies which
evaluated subjects based on a prior diagnosis of pancreatitis with
or without a control group. Patients with PS CF who developed
pancreatitis were more likely to carry mild (PIP score≤0.25) than
severe (PIP score N0.25) genotypes (Fig. 2A). In addition, patients
carrying mild genotypes had a significantly higher cumulative
proportion and 71% increase in risk of developing pancreatitis at
any given time (hazard ratio=2.4) than those with moderate–
severe genotypes. Further evidence of an association between the
severity of CFTR genotypes and the risk of pancreatitis was
observed when patients were sub-stratified according to the
severity of each CFTR allele. The presence of mild mutations on
both alleles conferred a significantly higher cumulative proportionand greater risk of pancreatitis than those with mild/severe and
severe/severe alleles. In fact, there appeared to be a gradation of
risk of developing pancreatitis according to genotype severity
(Fig. 2B). At any given time, patients carrying mild mutations on
both alleles (mild/mild) had the greatest risk of pancreatitis
(hazard ratio=4.2) which is followed by patients carrying one
mild (mild/severe; hazard ratio=1.9), when compared with those
who carried severe mutations on both alleles. This finding was
also supported by another recent study reporting R75Q, a mild
mutation, being significantly associated with chronic pancreatitis
[30]. Although R75Q has been suggested to be a specific
pancreatitis-associated mutation due to selective bicarbonate
conductance defect, there have been patients not affected by
pancreatitis identified with this mutation who presented with
other single organ manifestations of CF in adulthood such as
chronic sinopulmonary disease [31].
Other phenotypic differences between PS CF patients with
and without pancreatitis supported the contention that, as a group,
those at risk of pancreatitis carried milder mutations. Patients
with pancreatitis were diagnosed with CF at a significantly older
age than those without pancreatitis (median (IQR) ages at
diagnosis of 14.9 (9.5–27.7) vs. 9.3 (1.5–21.4); P=0.003).
Furthermore, patients with pancreatitis had a significantly lower
mean (SD) sweat chloride than patients without pancreatitis (74.5
(26.2) vs. 82.8 (25.2) mmol/L; P=0.03).
This study provided novel insight into the overall pathogenic
role of CFTR in pancreatitis not only in CF but also among those
with “idiopathic” pancreatitis associated with CFTR-mutations
(Fig. 3). The findings are consistent with the hypothesis that risk of
pancreatitis is related to the balance between degree of pancreatic
acinar preservation and severity of pancreatic ductal (and/or
ductular) obstruction, both of which are associated with the range
of severity of CFTR dysfunction, but in opposing directions.
Among subjects who carry sufficient CFTR function to confer PS,
there is a risk of pancreatitis when sufficient pancreatic acinar
tissue is present for obstructive ductal lesions to cause disease.
Based upon this concept, the risk of pancreatitis will increase with
milder CFTR dysfunction, correlating with greater pancreatic
acinar reserve. At some point, the risk of CFTR-associated
pancreatitis lessens when there is sufficient ductal flow to prevent
development of obstructive disease necessary for pancreatitis.
However, as discussed below, dysfunctional CFTR is only one of
a number of other genetic and environmental factors that
contribute to the risk of pancreatitis. These other modifying
factors also help determine the heterogeneity of end-organ disease
(exocrine pancreas, sinopulmonary tract, liver etc.) in all CF
affected organs.
6. Genetic and/or environmental modifiers for CF and
CFTR-related pancreatitis
Various CF modifier genes have been identified that
influence disease manifestation and severity in CF-affected
organs such as lung disease, liver cirrhosis, meconium ileus and
CF-related diabetes. The development of pancreatitis among
those who carry CFTR mutations is not an exception. Not all
PS CF patients who carry mild genotypes develop pancreatitis,
361C.Y. Ooi, P.R. Durie / Journal of Cystic Fibrosis 11 (2012) 355–362as widely observed in clinical practice and confirmed by a
recent study [19], suggesting additional influences on pheno-
type by non-CFTR modifier factors (genetic and/or environ-
mental) even in a monogenic disease such as CF. For example,
the risk for developing recurrent-acute or chronic pancreatitis
has been reported to be greater in individuals who carry
mutations in both the CFTR and SPINK1 genes [27,32]. Other
genetic factors are likely to play a role but remain to be
determined. The interactions with environmental factors such
as cigarette smoking, alcohol and diet are highly complex, and
are only beginning to unravel.
7. Clinical characteristics of pancreatitis in CF
Symptomatic pancreatitis in CF remains an under-recognized
condition and diagnosis requires a high index of suspicion. It
occurs in 20% of PS CF patients, with a quarter presenting with
pancreatitis prior to the diagnosis of CF, typically at later childhood
and adulthood [19]. Abdominal pain, usually located in the
epigastric region, associated with varying degrees of nausea and
vomiting are the typical symptoms. There is variation in the agreed
“cut-off” value of serum pancreatic enzyme concentrations, among
various consensus documents and publications, for confirming the
diagnosis of acute pancreatitis [19,21,33,34]. This generally ranges
from≥ two times to≥ three times above the upper limit of normal.
Imaging evidence of acute inflammation of the pancreas also helps
to confirm the diagnosis of acute pancreatitis. Imaging of the
pancreas in PI CF patients invariably show chronic changes of
pancreatitis (e.g. atrophy, calcification and duct abnormalities)
[35]. However, these findings are not necessarily indicative of
clinical pancreatitis since there is already significant destruction
and loss of exocrine pancreatic tissue.
8. Prognosis
Based on a large cohort of PS CF with pancreatitis [19], the
majority of affected patients have been reported to develop
recurrent-acute pancreatitis (60%); another 20% experienced a
single episode of acute pancreatitis and 20% showed progression to
chronic pancreatitis. In usual circumstances, PS CF patients who
carry mild genotypes are expected to remain PS. However, in the
presence of symptomatic pancreatitis, there is an increased risk
(odds ratio=5.5) of PS CF patients developing exocrine pancreatic
insufficiency. The progression from PS to PI was reported to occur
at least a decade after the first documented episode of pancreatitis.
9. Pancreatic cancer
Due to the relatively young age of the CF patient population, the
absolute risk of malignancy has been low. However, as age of
survival of CF patients continues to increase, it has become
recognized that there is an increased risk of malignancy in the
gastrointestinal and biliary tracts [36]. Interestingly, the risk of
malignancy in the pancreas was reported, in a sub-analysis, to be
greater than the overall risk of cancer in the digestive tract (odds
ratio (95% CI) of 31.5 (4.8–205) vs. 6.4 (2.9–14), respectively).
Due to the nature of the study, the exocrine pancreatic status (PI vs.PS) of patients with pancreatic cancer was not reported. Since
chronic pancreatitis is a risk factor for pancreatic cancer, we
speculate that PI CF patients have the greatest risk due to the early
onset (in-utero) of chronic inflammation in the pancreas.
Nevertheless, the risk of pancreatic cancer also appears to be
raised among non-CF individuals who carry 1 or 2 CFTR
mutations. In a prospective study of 949 patients with pancreatic
adenocarcinoma, there was a modest increase in risk of pancreatic
adenocarcinoma among those who carried CFTR mutation(s)
(odds ratio (95% CI) of 1.82 (1.14–2.94)) [37]. Carriers of CFTR
mutations were seen to be diagnosed at a younger age than non-
carriers, with the effect exclusively seen in ever-smokers,
suggesting the additive modifying effects of cigarette smoking.
10. Areas for future research
Greater insights into underlying molecular mechanisms are
much needed. The complex interactions between various genetic
and environmental factors that influence disease manifestation and
severity remain to be determined. Multicenter collaborations, with
careful phenotyping and genotyping of subjects, are necessary for
such studies given this relatively uncommon manifestation of CF.
Genetic association studies aimed at identifying novel CFTR
mutation-associated pancreatitis have potential therapeutic impli-
cations, especially in the era of targeted drug design. Currently,
there is no specific therapy available for pancreatitis. Given the
exciting advances in therapies aimed at improving CFTR [38], we
wonder whether these forms of therapy could be applied to
prevent, reduce risk or ameliorate pancreatitis. This is an important
consideration given that a large subset of patients with so-called
“idiopathic” pancreatitis carries mild CFTR mutations on at least
one allele. In addition, the role of genetic tests for disease
stratification and prognostication remains to be explored.
11. Conclusion
There has been a vast expansion in our understanding of the
wide range of phenotypes associated with CFTR dysfunction
since the discovery of the CFTR gene. Pancreatitis is one such
phenotype, which is seen almost exclusively among PS CF
patients. The relationship between the severity of CFTR
genotypes and the risk of pancreatitis has been established. The
genotype–phenotype correlation in pancreatitis is unique com-
pared to other organ manifestations but is still consistent with the
complex monogenic nature of CF. Paradoxically, genotypes
associated with otherwise mild phenotypic effects have the
greater risk for causing pancreatitis; compared with genotypes
associated with moderate to severe disease phenotypes. Greater
understanding into the underlyingmechanisms of disease is much
needed. The emergence of CFTR-assist therapies may potentially
have a significant therapeutic role in the treatment of all forms of
CFTR-mutation associated pancreatitis.
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